Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIO Trial: Olaparib, Radiation, and Immunotherapy in ES-SCLC
NCT04728230Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2021
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in small cell lung cancer (SCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2021; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04728230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728230.